|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0014822,
umls-concept:C0019004,
umls-concept:C0024501,
umls-concept:C0030705,
umls-concept:C0060241,
umls-concept:C0302583,
umls-concept:C0332174,
umls-concept:C0348016,
umls-concept:C0449438,
umls-concept:C0547047,
umls-concept:C0721534,
umls-concept:C1514873,
umls-concept:C1524112,
umls-concept:C1708745
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2006-9-20
|
|
pubmed:abstractText |
Haemodialysis patients need sustained treatment with intravenous iron because iron deficiency limits the efficacy of recombinant human epoetin therapy in these patients. However, the optimal intravenous iron maintenance dose has not been established yet.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Erythropoietin,
http://linkedlifedata.com/resource/pubmed/chemical/Ferric Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Ferritins,
http://linkedlifedata.com/resource/pubmed/chemical/Hematinics,
http://linkedlifedata.com/resource/pubmed/chemical/Hemoglobins,
http://linkedlifedata.com/resource/pubmed/chemical/Iron,
http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Transferrin,
http://linkedlifedata.com/resource/pubmed/chemical/darbepoetin alfa,
http://linkedlifedata.com/resource/pubmed/chemical/epoetin alfa,
http://linkedlifedata.com/resource/pubmed/chemical/epoetin beta,
http://linkedlifedata.com/resource/pubmed/chemical/ferric oxide, saccharated
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0931-0509
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
21
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2841-5
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16891647-Adolescent,
pubmed-meshheading:16891647-Adult,
pubmed-meshheading:16891647-Aged,
pubmed-meshheading:16891647-Dose-Response Relationship, Drug,
pubmed-meshheading:16891647-Drug Administration Schedule,
pubmed-meshheading:16891647-Erythropoietin,
pubmed-meshheading:16891647-Female,
pubmed-meshheading:16891647-Ferric Compounds,
pubmed-meshheading:16891647-Ferritins,
pubmed-meshheading:16891647-Hematinics,
pubmed-meshheading:16891647-Hemoglobins,
pubmed-meshheading:16891647-Humans,
pubmed-meshheading:16891647-Injections, Intravenous,
pubmed-meshheading:16891647-Iron,
pubmed-meshheading:16891647-Male,
pubmed-meshheading:16891647-Middle Aged,
pubmed-meshheading:16891647-Prospective Studies,
pubmed-meshheading:16891647-Recombinant Proteins,
pubmed-meshheading:16891647-Renal Dialysis,
pubmed-meshheading:16891647-Transferrin,
pubmed-meshheading:16891647-Treatment Outcome
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
|
|
pubmed:affiliation |
Canonical Hospital of Walenstadt, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase IV
|
